Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer
Open Access
- 25 April 2006
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 94 (10), 1550-1552
- https://doi.org/10.1038/sj.bjc.6603114
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?British Journal of Cancer, 2006
- Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2Clinical Cancer Research, 2004
- Allogeneic hematopoietic stem cell transplantation for metastatic breast cancer.2004
- HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic MiceThe Journal of Immunology, 2003
- Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.2003
- Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanesBritish Journal of Cancer, 2002
- Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based VaccinesJournal of Clinical Oncology, 2002
- Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.2002
- The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.2001